Aplasias Medulares

8/6/2019 Aplasias Medulares

1/36

Dvidas

[email protected]

Arquivo

Tratamento das Aplasias Medulares

Tratamento das Anemias

Anticoagulantes e antitrombticos

Site

www.gilbertodenucci.com

Dvidas

[email protected]

Arquivo

Tratamento das Aplasias Medulares

Tratamento das Anemias

Anticoagulantes e antitrombticos

Site

www.gilbertodenucci.com


2/36

Structures of folate, tetrahydrofolate, and its analogue

methotrexate

Williams Hematology chapter 20

The vitamin is absorbed as a monoglutamate and converted intracellularly to a polyglutamate, in

which form it is both physiologically active and is stored in cells.


3/36


4/36

Mechanim of action of alkylating agents



5/36

Thalidomide and lenalidomide



6/36

BCR-ABL tyrosine kinase

inhibitors



7/36

Dose and Toxicity of FDA-Approved Monoclonal

Antibody-Based Drugs

Williams Hematology chapter 20 T


8/36

Effect of Drugs on Warfarin Response



9/36

Recommended INR Values during Oral Anticoagulant

Therapy



10/36

Reversing Warfarin Therapy



11/36

Low-molecular-Weght

Heparin Regimens



12/36

Clinical Indications and Use of Direct Thrombin

inhibitors



13/36

Antiplatelet Agents by Mechanism of Action and

Clinical Use



14/36

Antiplatelet Agents, Approved Dosing



15/36

Drugs Associated with Aplastic Anemia


I h i f i f CD34 l i i l


16/36

Immune pathogenesis of apoptosis of CD34 multipotential

hematopoietic cells in acquired aplastic anemia


P b bilit f i l ft h t i ti t ll t l ti f


17/36

Probability of survival after hematopoietic stem cell transplation for severe

aplastic anemia by donor type and age, 1998-2004.



18/36

Near of

Publication

2008

2007

2007

2007

20062006

Response tom Immunotherapy in Patients with Severe Aplastic

Anemia


Representation of the FA/BRCA pathway Following when a replication fork encounter


19/36

Representation of the FA/BRCA pathway . Following when a replication fork encounter

a DNA cross-link, ATR (ataxia telangiectasia and rad3-related proteins) is activated


Representation of the interaction between dyskerin and the other molecules


20/36

Representation of the interaction between dyskerin and the other molecules

(GAR1, NHP2, NOP10, TERC, and TERT) of the telomerase complex (and

their association with different disease categories).



21/36

Iron Compartments in Normal Man



22/36

Schematic of human isoferritins of different subunit compositions



23/36

Schematic of iron uptake from the intestine and transfer to the

plasma by na intestinal villus cell



24/36

The relationship between oral iron dosage and amount of iron

absorbed in humans


The iron cycle in humans Iron is tightly conserved in a nearly closed system in which eac


25/36

The iron cycle in humans. Iron is tightly conserved in a nearly closed system in which eac

iron atom cycles repeatedly from plasma and extracellullar fluid (ECF) to the marrow,

where it is incorporated into hemoglobin



26/36

The transferrin cycle



27/36

The regulation of iron metabolism at the

cytoplasmic mRNA level by interaction of

iron-regulatory protein (IRP-1) and the iron-

responsive elements (IREs) to apoferritin

mRNA (A) and transferrin receptor (TfR)

mRNA (B)

Th t l t t th t i th i i l t f


28/36

The stem-loop structure that is the iron-responsive elements of

apoferritin mRNA.



29/36

Prevalence of iron Deficiency

and Iron-Deficiency Anemia in

Some Selected Population


30/36

Daily Dietary Iron Intake in the United States, Mean Values for

Selected Groups



31/36

Frequency of Some Finfings Commonly Ascribed to iron Deficiency in

White Women Aged 20-49 Attending a Health Appraisal Clinic


Erythrocyte indices in iron-deficiency anemia of adults data obtained wich


32/36

Erythrocyte indices in iron-deficiency anemia of adults, data obtained wich

Coulter Counter, Model S.

Williams Hematology chapter 42 F

Rate of response of patient with iron-deficiency anemia to 43 days of treatment with


33/36

p p y y

prolonged-release Feosol spansules (containing 325 mg ferrous sulfate), one capsule daily,

the dosage recommended by the manufacturer, followed by 43 days of treatment with

nonenteric ferrous sulfate (0.3 g three times daily).

Williams Hematology chapter 42 F

Stages in the development of iron deficiency


34/36

Stages in the development of iron deficiency



35/36

Iron Preparations for Pediatric Use

Williams Hematology chapter 42 Ta


36/36

Aplasias Medulares

Documents

Transcript of Aplasias Medulares